Functional muscle ischemia in Duchenne and Becker muscular dystrophy

Gail D Thomas, Gail D Thomas

Abstract

Duchenne and Becker muscular dystrophy (DMD/BMD) comprise a spectrum of devastating X-linked muscle wasting disease for which there is no treatment. DMD/BMD is caused by mutations in the gene encoding dystrophin, a cytoskeletal protein that stabilizes the muscle membrane and also targets other proteins to the sarcolemma. Among these is the muscle-specific isoform of neuronal nitric oxide synthase (nNOSμ) which binds spectrin-like repeats within dystrophin's rod domain and the adaptor protein α-syntrophin. Dystrophin deficiency causes loss of sarcolemmal nNOSμ and reduces paracrine signaling of muscle-derived nitric oxide (NO) to the microvasculature, which renders the diseased muscle fibers susceptible to functional muscle ischemia during exercise. Repeated bouts of functional ischemia superimposed on muscle fibers already weakened by dystrophin deficiency result in use-dependent focal muscle injury. Genetic and pharmacologic strategies to boost nNOSμ-NO signaling in dystrophic muscle alleviate functional muscle ischemia and show promise as novel therapeutic interventions for the treatment of DMD/BMD.

Keywords: Duchenne muscular dystrophy; exercise; functional sympatholysis; neuronal nitric oxide synthase; sympathetic vasoconstriction.

Figures

Figure 1
Figure 1
Left panel, in healthy muscle, nNOSμ is localized to the sarcolemma by association with the rod domain of dystrophin and the PDZ domain of α-syntrophin (syn). During muscle contraction, some of the nNOSμ-derived nitric oxide (NO) diffuses to the nearby microvessels where it increases cGMP and attenuates norepinephrine (NE)-mediated vasoconstriction. This NO-mediated functional sympatholysis optimizes blood flow in the working muscles. Right panel, in dystrophic muscle, nNOSμ is reduced in amount and mislocalized from the sarcolemma to the cytosol. Less NO is generated during muscle contraction, resulting in unrestrained sympathetic vasoconstriction and transient functional muscle ischemia, which may exacerbate injury of the diseased muscle fibers. Genetic and pharmacologic interventions targeting different aspects of nNOSμ-NO signaling that alleviate functional muscle ischemia in preclinical studies are shown. sGC, soluble guanylyl cyclase; DG, dystroglycan; PDE, phosphodiesterase.

References

    1. Adamo C. M., Dai D. F., Percival J. M., Minami E., Willis M. S., Patrucco E., et al. (2010). Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. U.S.A. 107, 19079–19083 10.1073/pnas.1013077107
    1. Adams M. E., Mueller H. A., Froehner S. C. (2001). In vivo requirement of the α-syntrophin PDZ domain for the sarcolemmal localization of nNOS and aquaporin-4. J. Cell Biol. 155, 113–122 10.1083/jcb.200106158
    1. Anderson J. E. (2000). A role for nitric oxide in muscle repair: nitric oxide-mediated activation of muscle satellite cells. Mol. Biol. Cell 11, 1859–1874 10.1091/mbc.11.5.1859
    1. Archer J. D., Vargas C. C., Anderson J. E. (2006). Persistent and improved functional gain in mdx dystrophic mice after treatment with L-arginine and deflazacort. FASEB J. 20, 738–740 10.1096/fj.05-4821fje
    1. Asai A., Sahani N., Kaneki M., Ouchi Y., Martyn J. A., Yasuhara S. E. (2007). Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy. PLoS ONE 2:e806 10.1371/journal.pone.0000806
    1. Bagher P., Duan D., Segal S. S. (2011). Evidence for impaired neurovascular transmission in a murine model of Duchenne muscular dystrophy. J. Appl. Physiol. 110, 601–609 10.1152/japplphysiol.01106.2010
    1. Barton E. R., Morris L., Kawana M., Bish L. T., Toursel T. (2005). Systemic administration of L-arginine benefits mdx skeletal muscle function. Muscle Nerve 32, 751–760 10.1002/mus.20425
    1. Benabdellah F., Yu H., Brunelle A., Laprevote O., De La Porte S. (2009). MALDI reveals membrane lipid profile reversion in MDX mice. Neurobiol. Dis. 36, 252–258 10.1016/j.nbd.2009.07.013
    1. Blake D. J., Weir A., Newey S. E., Davies K. E. (2002). Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev. 82, 291–329 10.1152/physrev.00028.2001
    1. Bradley W. G., O'Brien M. D., Walder D. N., Murchison D., Johnson M., Newell D. J. (1975). Failure to confirm a vascular cause of muscular dystrophy. Arch. Neurol. 32, 466–473 10.1001/archneur.1975.00490490070007
    1. Bramwell E. (1925). Muscular dystrophies, sympathetic system and endocrine glands. Lancet 209, 1103–1109
    1. Brenman J. E., Chao D. S., Xia H., Aldape K., Bredt D. S. (1995). Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell 82, 743–752 10.1016/0092-8674(95)90471-9
    1. Brunelli S., Sciorati C., D'Antona G., Innocenzi A., Covarello D., Galvez B. G., et al. (2007). Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. Proc. Natl. Acad. Sci. U.S.A. 104, 264–269 10.1073/pnas.0608277104
    1. Bushby K., Finkel R., Birnkrant D. J., Case L. E., Clemens P. R., Cripe L., et al. (2010a). Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 9, 77–93 10.1016/S1474-4422(09)70271-6
    1. Bushby K., Finkel R., Birnkrant D. J., Case L. E., Clemens P. R., Cripe L., et al. (2010b). Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol. 9, 177–189 10.1016/S1474-4422(09)70272-8
    1. Cacchiarelli D., Martone J., Girardi E., Cesana M., Incitti T., Morlando M., et al. (2010). MicroRNAs involved in molecular circuitries relevant for the Duchenne muscular dystrophy pathogenesis are controlled by the dystrophin/nNOS pathway. Cell Metab. 12, 341–351 10.1016/j.cmet.2010.07.008
    1. Cazzato G. (1968). Considerations about a possible role played by connective tissue proliferation and vascular disturbances in the pathogenesis of progressive muscular dystrophy. Eur. Neurol. 1, 158–179 10.1159/000113659
    1. Chang W. J., Iannaccone S. T., Lau K. S., Masters B. S. S., McCabe T. J., McMillan K., et al. (1996). Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy. Proc. Natl. Acad. Sci. U.S.A. 93, 9142–9147 10.1073/pnas.93.17.9142
    1. Chao D. S., Gorospe J. R., Brenman J. E., Rafael J. A., Peters M. F., Froehner S. C., et al. (1996). Selective loss of sarcolemmal nitric oxide synthase in Becker muscular dystrophy. J. Exp. Med. 184, 609–618 10.1084/jem.184.2.609
    1. Chavoshan B., Sander M., Sybert T. E., Hansen J., Victor R. G., Thomas G. D. (2002). Nitric oxide-dependent modulation of sympathetic neural control of oxygenation in exercising human skeletal muscle. J. Physiol. 540, 377–386 10.1113/jphysiol.2001.013153
    1. Colussi C., Mozzetta C., Gurtner A., Illi B., Rosati J., Straino S., et al. (2008). HDAC2 blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment. Proc. Natl. Acad. Sci. U.S.A. 105, 19183–19187 10.1073/pnas.0805514105
    1. D'Angelo M. G., Gandossini S., Martinelli Boneschi F., Sciorati C., Bonato S., Brighina E., et al. (2012). Nitric oxide donor and nonsteroidal anti inflammatory drugs as a therapy for muscular dystrophies: evidence from a safety study with pilot efficacy measures in adult dystrophic patients. Pharmacol. Res. 65, 472–479 10.1016/j.phrs.2012.01.006
    1. Demos J. (1961). Mesures des temps de circulation chez 79 myopathes. Etude statistique des resultats. role du degre de l'atteinte musculaire clinique, du mode evolutif de la maladie, du sexe du malade, des saisons. Rev. Fr. Etudes Clin. Biol. 6, 876–887
    1. Demos J., Escoiffier J. (1957). Troubles circulatoires au cours de la myopathie: etudes arteriographiques. Rev. Fr. Etudes Clin. Biol. 2, 489–494
    1. Emery A. E., Schelling J. L. (1965). Limb blood flow in patients and carriers of Duchenne muscular dystrophy. Acta Genet. Stat. Med. 15, 337–344
    1. Engel W. K. (1967). Muscle biopsies in neuromuscular diseases. Pediatr. Clin. North Am. 14, 963–995
    1. Guerron A. D., Rawat R., Sali A., Spurney C. F., Pistilli E., Cha H. J., et al. (2010). Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne Muscular Dystrophy. PLoS ONE 5:e11220 10.1371/journal.pone.0011220
    1. Hathaway P. W., Engel W. K., Zellweger H. (1970). Experimental myopathy after microarterial embolization; comparison with childhood x-linked pseudohypertrophic muscular dystrophy. Arch. Neurol. 22, 365–378 10.1001/archneur.1970.00480220079011
    1. Hnia K., Gayraud J., Hugon G., Ramonatxo M., De La Porte S., Matecki S., et al. (2008). L-arginine decreases inflammation and modulates the nuclear factor-kappaB/matrix metalloproteinase cascade in mdx muscle fibers. Am. J. Pathol. 172, 1509–1519 10.2353/ajpath.2008.071009
    1. Jerusalem F., Engel A. G., Gomez M. R. (1974). Duchenne dystrophy. I. Morphometric study of the muscle microvasculature. Brain 97, 115–122 10.1093/brain/97.1.115
    1. Kameya S., Miyagoe Y., Nonaka I., Ikemoto T., Endo M., Hanaoka K., et al. (1999). α1-syntrophin gene disruption results in the absence of neuronal-type nitric oxide synthase at the sarcolemma but does not induce muscle degeneration. J. Biol. Chem. 274, 2193–2200 10.1074/jbc.274.4.2193
    1. Kapuscinska B., Kapuscinski A., Stroinska B. (1970). Determination of blood flow in muscles using radioactive xenon (133Xe) in cases of progressive muscular dystrophy. Pol. Med. J. 9, 506–511
    1. Kawahara G., Karpf J. A., Myers J. A., Alexander M. S., Guyon J. R., Kunkel L. M. (2011). Drug screening in a zebrafish model of Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. U.S.A. 108, 5331–5336 10.1073/pnas.1102116108
    1. Keeble J. E., Moore P. K. (2002). Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. Br. J. Pharmacol. 137, 295–310 10.1038/sj.bjp.0704876
    1. Khairallah M., Khairallah R. J., Young M. E., Allen B. G., Gillis M. A., Danialou G., et al. (2008). Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency. Proc. Natl. Acad. Sci. U.S.A. 105, 7028–7033 10.1073/pnas.0710595105
    1. Kobayashi Y. M., Rader E. P., Crawford R. W., Iyengar N. K., Thedens D. R., Faulkner J. A., et al. (2008). Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature 456, 511–515 10.1038/nature07414
    1. Koehler J. (1977). Blood vessel structure in Duchenne muscular dystrophy. I. Light and electron microscopic observations in resting muscle. Neurology 27, 861–868 10.1212/WNL.27.9.861
    1. Koenig M., Hoffman E. P., Bertelson C. J., Monaco A. P., Feener C., Kunkel L. M. (1987). Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50, 509–517 10.1016/0092-8674(87)90504-6
    1. Lai Y., Thomas G. D., Yue Y., Yang H. T., Li D., Long C., et al. (2009). Dystrophins carrying spectrin-like repeats 16/17 anchor nNOS to the sarcolemma and enhance exercise performance. J. Clin. Invest. 119, 624–635 10.1172/JCI36612
    1. Lai Y., Zhao J., Yue Y., Duan D. (2013). α2 and α3 helices of dystrophin R16 and R17 frame a microdomain in the α1 helix of dystrophin R17 for neuronal NOS binding. Proc. Natl. Acad. Sci. U.S.A. 110, 525–530 10.1073/pnas.1211431109
    1. Leinonen H., Juntunen J., Somer H., Rapola J. (1979). Capillary circulation and morphology in Duchenne muscular dystrophy. Eur. Neurol. 18, 249–255 10.1159/000115084
    1. Li D., Yue Y., Lai Y., Hakim C. H., Duan D. (2011). Nitrosative stress elicited by nNOSmicro delocalization inhibits muscle force in dystrophin-null mice. J. Pathol. 223, 88–98 10.1002/path.2799
    1. Marques M. J., Luz M. A., Minatel E., Neto H. S. (2005). Muscle regeneration in dystrophic mdx mice is enhanced by isosorbide dinitrate. Neurosci. Lett. 382, 342–345 10.1016/j.neulet.2005.03.023
    1. Martin E. A., Barresi R., Byrne B. J., Tsimerinov E. I., Scott B. L., Walker A. E., et al. (2012). Tadalafil alleviates muscle ischemia in patients with Becker muscular dystrophy. Sci. Transl. Med. 4, 162ra155 10.1126/scitranslmed.3004327
    1. Mendell J. R., Engel W. K., Derrer E. C. (1971). Duchenne muscular dystrophy: functional ischemia reproduces its characteristic lesions. Science 172, 1143–1145 10.1126/science.172.3988.1143
    1. Mendell J. R., Engel W. K., Derrer E. C. (1972). Increased plasma enzyme concentrations in rats with functional ischaemia of muscle provide a possible model of Duchenne muscular dystrophy. Nature 239, 522–524 10.1038/239522a0
    1. Mizunoya W., Upadhaya R., Burczynski F. J., Wang G., Anderson J. E. (2011). Nitric oxide donors improve prednisone effects on muscular dystrophy in the mdx mouse diaphragm. Am. J. Physiol., Cell Physiol. 300, C1065–C1077 10.1152/ajpcell.00482.2010
    1. Monaco A. P., Neve R. L., Colletti-Feener C., Bertelson C. J., Kurnit D. M., Kunkel L. M. (1986). Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature 323, 646–650 10.1038/323646a0
    1. Munzel T., Daiber A., Mulsch A. (2005). Explaining the phenomenon of nitrate tolerance. Circ. Res. 97, 618–628 10.1161/01.RES.0000184694.03262.6d
    1. Musch B. C., Papapetropoulos T. A., McQueen D. A., Hudgson P., Weightman D. (1975). A comparison of the structure of small blood vessels in normal, denervated and dystrophic human muscle. J. Neurol. Sci. 26, 221–234 10.1016/0022-510X(75)90034-9
    1. Palladino M., Gatto I., Neri V., Straino S., Smith R. C., Silver M., et al. (2013). Angiogenic impairment of the vascular endothelium: a novel mechanism and potential therapeutic target in muscular dystrophy. Arterioscler. Thromb. Vasc. Biol. 33, 2867–2876 10.1161/ATVBAHA.112.301172
    1. Paulson O. B., Engel A. G., Gomez M. R. (1974). Muscle blood flow in Duchenne type muscular dystrophy, limb-girdle dystrophy, polymyositis, and in normal controls. J. Neurol. Neurosurg. Psychiatr. 37, 685–690 10.1136/jnnp.37.6.685
    1. Petrof B. J., Shrager J. B., Stedman H. H., Kelly A. M., Sweeney H. L. (1993). Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl. Acad. Sci. U.S.A. 90, 3710–3714 10.1073/pnas.90.8.3710
    1. Powers S. K., Jackson M. J. (2008). Exercise-induced oxidative stress: cellular mechanisms and impact on muscle force production. Physiol. Rev. 88, 1243–1276 10.1152/physrev.00031.2007
    1. Rando T. A. (2001). Role of nitric oxide in the pathogenesis of muscular dystrophies: a “two hit” hypothesis of the cause of muscle necrosis. Microsc. Res. Tech. 55, 223–235 10.1002/jemt.1172
    1. Rando T. A. (2002). Oxidative stress and the pathogenesis of muscular dystrophies. Am. J. Phys. Med. Rehabil. 81, S175–186 10.1097/00002060-200211001-00018
    1. Ravipati G., McClung J. A., Aronow W. S., Peterson S. J., Frishman W. H. (2007). Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. Cardiol. Rev. 15, 76–86 10.1097/01.crd.0000233904.77128.49
    1. Sander M., Chavoshan B., Harris S. A., Iannoccone S. T., Stull J. T., Thomas G. D., et al. (2000). Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. Proc. Natl. Acad. Sci. U.S.A. 97, 13818–13823 10.1073/pnas.250379497
    1. Sciorati C., Miglietta D., Buono R., Pisa V., Cattaneo D., Azzoni E., et al. (2011). A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy. Pharmacol. Res. 64, 210–217 10.1016/j.phrs.2011.05.003
    1. Singh R. J., Hogg N., Joseph J., Konorev E., Kalyanaraman B. (1999). The peroxynitrite generator, SIN-1, becomes a nitric oxide donor in the presence of electron acceptors. Arch. Biochem. Biophys. 361, 331–339 10.1006/abbi.1998.1007
    1. Stamler J. S., Meissner G. (2001). Physiology of nitric oxide in skeletal muscle. Physiol. Rev. 81, 209–237
    1. Straino S., Germani A., Di Carlo A., Porcelli D., De Mori R., Mangoni A., et al. (2004). Enhanced arteriogenesis and wound repair in dystrophin-deficient mdx mice. Circulation 110, 3341–3348 10.1161/01.CIR.0000147776.50787.74
    1. Suzuki N., Motohashi N., Uezumi A., Fukada S., Yoshimura T., Itoyama Y., et al. (2007). NO production results in suspension-induced muscle atrophy through dislocation of neuronal NOS. J. Clin. Invest. 117, 2468–2476 10.1172/JCI30654
    1. Thomas G. D., Sander M., Lau K. S., Huang P. L., Stull J. T., Victor R. G. (1998). Impaired metabolic modulation of α-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. Proc. Natl. Acad. Sci. U.S.A. 95, 15090–15095 10.1073/pnas.95.25.15090
    1. Thomas G. D., Shaul P. W., Yuhanna I. S., Froehner S. C., Adams M. E. (2003). Vasomodulation by skeletal muscle-derived nitric oxide requires α-syntrophin-mediated sarcolemmal localization of neuronal nitric oxide synthase. Circ. Res. 92, 554–560 10.1161/01.RES.0000061570.83105.52
    1. Thomas G. D., Victor R. G. (1998). Nitric oxide mediates contraction-induced attenuation of sympathetic vasoconstriction in rat skeletal muscle. J. Physiol. 506, 817–826 10.1111/j.1469-7793.1998.817bv.x
    1. Thomas G. D., Ye J., De Nardi C., Monopoli A., Ongini E., Victor R. G. (2012). Treatment with a nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse model of Duchenne muscular dystrophy. PLoS ONE 7:e49350 10.1371/journal.pone.0049350
    1. Tidball J. G., Wehling-Henricks M. (2004). Expression of a NOS transgene in dystrophin-deficient muscle reduces muscle membrane damage without increasing the expression of membrane-associated cytoskeletal proteins. Mol. Genet. Metab. 82, 312–320 10.1016/j.ymgme.2004.06.006
    1. Torelli S., Brown S. C., Jimenez-Mallebrera C., Feng L., Muntoni F., Sewry C. A. (2004). Absence of neuronal nitric oxide synthase (nNOS) as a pathological marker for the diagnosis of Becker muscular dystrophy with rod domain deletions. Neuropathol. Appl. Neurobiol. 30, 540–545 10.1111/j.1365-2990.2004.00561.x
    1. Voisin V., Sebrie C., Matecki S., Yu H., Gillet B., Ramonatxo M., et al. (2005). L-arginine improves dystrophic phenotype in mdx mice. Neurobiol. Dis. 20, 123–130 10.1016/j.nbd.2005.02.010
    1. Wallace J. L., Viappiani S., Bolla M. (2009). Cyclooxygenase-inhibiting nitric oxide donators for osteoarthritis. Trends Pharmacol. Sci. 30, 112–117 10.1016/j.tips.2009.01.001
    1. Wehling M., Spencer M. J., Tidball J. G. (2001). A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. J. Cell Biol. 155, 123–131 10.1083/jcb.200105110
    1. Wehling-Henricks M., Jordan M. C., Roos K. P., Deng B., Tidball J. G. (2005). Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium. Hum. Mol. Genet. 14, 1921–1933 10.1093/hmg/ddi197
    1. Zhang Y., Yue Y., Li L., Hakim C. H., Zhang K., Thomas G. D., et al. (2013). Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy. Hum. Mol. Genet. 22, 3720–3729 10.1093/hmg/ddt224

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj